Background Prolonged DAPT is undesirable in some patients. A biolimus-A9 drug-coated stent (BA9-DCS) has a rapid drug-elution profile potentially allowing shortened DAPT.
Methods Data were gathered prospectively for 410 patients deemed to be at high risk of bleeding treated with a BA9-DCS stent at 2 UK centres and compared to usual PCI patients.
Results BA9-DCS indications included warfarin therapy, age and anaemia. Patients receiving a BA9-DCS were older (71.6 ± 11.8 vs. 64.8 ± 11.6yrs, p < 0.001), more often female (38.2 vs. 26.8%, P < 0.001) and to have comorbidity including hypertension, chronic kidney disease or poor LV function than usual PCI patients. The baseline Mehran bleed risk score was also significantly higher in the BA9-DCS group (19.4 ± 8.7 vs. 13.1 ± 5.8, p < 0.001). Of the BA9-DCS cohort, 95.5% of patients demonstrated disease fitting NICE criteria for DES eligibility. The number of lesions treated (1.81 ± 1.1 vs. 1.58 ± 0.92, p = 0.003), total lesion length (32.1 ± 21.7 vs. 26.1 ± 17.6mm, p < 0.001), number of stents used (1.93 ± 1.11 vs. 1.65 ± 1.4, p-0.007) and total stent length (37.5 ± 20.8 vs. 32.4 ± 20.3, p < 0.01) were greater for BA9-DCS patients. DAPT was prescribed for 3.3 ± 3.9 months for BA9-DCS patients and 11.3 ± 2.4 months for usual PCI patients (p < 0.001). At follow up of 392 ± 124 days event rates were low with ischemia-driven restenosis PCI occurring in 6 patients (2.4%), definite/probable stent thrombosis in 2 patients (0.8%) and death in 13 patients (5.2%).
Conclusions Early outcomes using polymer-free BA9 drug-coated stents are encouraging. Further studies are warranted.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.